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Background: Predictive models are an integral part of current clinical practice and help determine optimal treatment
strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival
(OS), when in fact, these effects may change during follow-up (FU). Furthermore, breast cancer (BC) patients may experi-
ence events that alter their prognosis from that time onwards. We investigated the ‘dynamic’ effects of different covariates
on OS and developed a nomogram to calculate 5-year dynamic OS (DOS) probability at different prediction timepoints (tP)
during FU.
Methods: Dutch and Belgian postmenopausal, endocrine-sensitive, early BC patients enrolled in the TEAM trial were
included. We assessed time-varying effects of specific covariates and obtained 5-year DOS predictions using a propor-
tional baselines landmark supermodel. Covariates included age, histological grade, hormone receptor and HER2 status,
T- and N-stage, locoregional recurrence (LRR), distant recurrence, and treatment compliance. A nomogram was
designed to calculate 5-year DOS based on individual characteristics.
Results: A total of 2602 patients were included (mean FU 6.2 years). N-stage, LRR, and HER2 status demonstrated
time-varying effects on 5-year DOS. Hazard ratio (HR) functions for LRR, high-risk N-stage (N2/3), and HER2 positivity
were HR = (8.427 × 0.583tP Þ, HR = (3.621 × 0.816tP Þ, and HR = (1.235 × 0.851tP Þ, respectively. Treatment discontinuation
was associated with a higher mortality risk, but without a time-varying effect [HR 1.263 (0.867–1.841)]. All other covari-
ates were time-constant.
Discussion: The current nomogram accounts for elapsed time since starting adjuvant endocrine treatment and opti-
mizes prediction of individual 5-year DOS during FU for postmenopausal, endocrine-sensitive BC patients. The nomo-
gram can facilitate in determining whether further therapy will benefit an individual patient, although validation in an
independent dataset is still needed.
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introduction
Breast cancer (BC) comprises a heterogeneous disease with
diverse features that can interact with outcomes, making it difficult
to obtain estimations of individual prognoses. The overwhelming
popularity of tools such as Adjuvant! or the Nottingham
Prognostic Index (NPI) illustrates the importance of prediction
models for physicians and patients, providing guidance for adju-
vant treatment decisions [1, 2]. Most prediction models, however,
cannot be used for cancer patients at specific time points during
the follow-up (FU) period, as these models have been designed for
use immediately after diagnosis. Apart from the caveats associated
with available ‘static’ prediction models, there are some important
reasons why these models may give misleading results when used
during FU. First, the fact that patients have already survived a
number of years after diagnosis may change a patient’s prognosis.
For instance, BC recurrence rates peak at 1–2 years after diagnosis
and decline thereafter, resulting in an improved prognosis [3–5].
Second, in the time between diagnosis and the moment of predic-
tion, important events may have taken place, such as locoregional
recurrence (LRR) and/or distant recurrences (DR) or premature
discontinuation of treatment, which may alter a patient’s progno-
sis. Third, some variables included in current models may exhibit
time-varying effects on outcome, resulting in a change in mortal-
ity risk as time progresses. Consequently, too much emphasis may†Both authors contributed equally.
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be placed on variables with a strong impact on outcome early in
the FU period, whereas this effect might be much smaller later on.
Available static models are based on probabilities of survival
at the time of diagnosis and may not accurately portray a
patient’s survival probability later on in the FU period. The
concept of updating survival probabilities by both incorporating
time-varying covariates and allowing for time-varying effects is
called dynamic prediction. By design, these variables are not
included in the static risk prediction models, and these consid-
erations illustrate a need for better prediction models for cancer
patients.
To investigate the clinical applicability of dynamic prediction, we
utilized a dataset from a large randomized clinical trial of postme-
nopausal hormone receptor-positive (HR+) early BC patients
treated with endocrine treatment (ET) in the Netherlands and
Belgium. The aim of the current analysis was to develop a clinically
applicable nomogram to facilitate the prediction of an individual
patient’s probability of surviving an additional 5 years at any pre-
diction timepoint (tP) up to 3 years after starting adjuvant ET. This
concept of continually updating 5-year overall survival (OS) from a
certain tP is referred to as 5-year dynamic overall survival (DOS).
We designed a dynamic predictive model, taking into account
various patient- and tumor-specific covariates with time-varying
and time-constant effects during FU.
methods
The Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial is a ran-
domized, phase III, multinational, open-label study conducted in postmeno-
pausal women with HR+ BC, who were eligible for adjuvant ET and
randomized to either 5 years of exemestane (25 mg) or 2.5–3 years of tam-
oxifen (20 mg) followed by exemestane (25 mg) for 2.5–2 years [6]. The
TEAM trial protocol was approved by regulatory and ethics authorities of all
participating centers in all participating countries. The trial was registered in
the Netherlands and Belgium with the Netherlands Trial register, NTR 267.
All patients provided written informed consent. Details of the study and
data collection have been published previously [6].
In the Netherlands and Belgium, 3168 postmenopausal, early BC patients
were enrolled in the TEAM trial. Patients who did not start randomized
treatment (n = 19) or had missing end point data (n = 4), metastatic disease
before the start of ET (n = 7), and patients with missing data regarding cov-
ariates used in the model (n = 528) were excluded (Figure 1). Patients with
estrogen receptor (ER) and progesterone receptor (PR)-negative disease
(n = 8) were excluded. Due to the unavailability of regular FU data by coun-
tries other than the Netherlands and Belgium beyond the initially planned
5 years of FU, the dynamic prediction model does not include data from all
participating TEAM trial countries (supplementary Table S1, available at
Annals of Oncology online).
The primary outcome of the present investigation was OS, which was the
time from randomization to the date of death or last recorded FU. LRR was
defined as any BC recurrence in the ipsilateral breast and/or lymph nodes as
well as in supraclavicular lymph nodes. LRR did not include ductal carcin-
oma in situ relapses. DR comprised all other accounts of BC recurrence.
statistical analysis
Statistical analyses were carried out using the programs SPSS (version 20)
and R (version 2.15.1). We used the proportional baselines landmark super-
model [7, 8] to obtain dynamic predictions of the 5-year DOS probability.
The model requires a number of landmark timepoints (tLM); in the current
model tLM was established at every third month between 0 and 3 years after
the start of ET. A prediction model for 5-year DOS at a specific tLM is con-
structed by selecting the individuals at risk at that tLM and incorporating the
values of any time-dependent covariates at that respective tLM in a Cox pro-
portional hazards model [9]. The landmark prediction models at different
tLMs may be combined into a single supermodel (supplementary Appendix
S1, available at Annals of Oncology online). Using this analysis in the clinical
setting, we can obtain DOS predictions at any prediction timepoint, tP,
2602 patients included in the 
analyses
Distant recurrence at the start of treatment 
(n = 7)
Missing primary endpoint data (n = 4)
ER- and PR-negative status (n = 8)
3168 patients included in the
study
Never started treatment (n = 19)
At least one missing covariate (n = 528)
Figure 1. CONSORT diagram of patients included in the analyses.
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between 0 and 3 years after starting adjuvant ET. For this specific model, the
prediction window was set to 5 years after the established tP.
Baseline patient- and tumor-specific factors included in the model com-
prised age at diagnosis (continuous, linear, and quadratic terms), Bloom &
Richardson (BR) histological grade (I, II, III), tumor stage (1, 2, 3/4), nodal
stage (N0, N1, N2/N3), ER and PR status (positive, negative), HER2 status
(positive, negative, missing), most extensive surgery (mastectomy, breast-
conserving surgery), and radiotherapy (yes, no), chemotherapy (yes, no). ER
and PR status were considered positive if at least 10% of tumor cells stained
positively following immunohistochemical staining, as defined by the Dutch
BC treatment guidelines [10].
The model also included three dynamic variables whose values may
change during ET, namely current ET status (on versus off ET), LRR (yes,
no), and DR (yes, no). To assess whether a patient had stopped treatment,
we used the last treatment date, as reported on the case-report forms. If no
last treatment date was available, the patient was assumed to be on-treat-
ment. According to the TEAM trial protocol, patients with LRR or DR dis-
continued or switched ET.
In order to test for time-varying covariate effects, interactions between
covariates and tLM (both linear and quadratic) were included in the model.
A backward selection procedure was then carried out in two steps. In the
first step, all quadratic tLM interactions with the covariates were tested.
Nonsignificant quadratic interactions were removed, and those covariates
which did not have significant interactions in the first step were then tested
in the second step for linear tLM interactions. Again, only significant interac-
tions were retained. Wald tests, based on robust standard errors, were used
and a P value of 0.05 was considered statistically significant (supplementary
Appendix S1, available at Annals of Oncology online). Main effects of the
covariates and of tLM and tLM2 were included, irrespective of statistical signifi-
cance. The model was then validated by internal calibration using the heuris-
tic shrinkage factor by van Houwelingen et al. [11]. The model’s ability to
correctly discriminate between patients was evaluated using the dynamic
cross-validated c-index. A c-index of 1 resembles a model that can perfectly
discriminate between patients, while with a c-index of 0.5, the prediction is
as good as chance [7].
nomogram
The nomogram is a user-friendly tool for calculating survival probabilities
based on a prediction model, and graphically computes 5-year DOS based
on an individual patient’s unique characteristics. For each prognostic factor,
a number of risk points are assigned to each corresponding covariate, which
can be read off the nomogram. The sum of the risk points represents a total
risk point score, from which the corresponding 5-year DOS probability can
be assessed at any tP (between 0 and 3 years) after the start of ET. A web-
based dynamic prediction tool based on the nomogram has been created to
facilitate the calculation of 5-year dynamic overall survival rates and aid in
the decision-making process in clinical practice (http://shiny.bioexp.nl/dsp/).
results
In total, 2602 TEAM trial patients with a median age of 64.8
years (range 38–92 years), were included in the analyses (Figure 1).
Baseline characteristics of included patients are depicted in
Table 1. The majority of patients included in this trial had adju-
vant radiotherapy (66%) and did not receive adjuvant chemother-
apy (68%). Figure 2 provides an overview of the total number of
patients in the landmark datasets at successive tLMs in relation
to treatment compliance and disease recurrence status.
Table 2 depicts the regression coefficients and hazard ratios
(HR) with 95% confidence intervals (95% CI) of the covariates
included in the model. Covariates with time-constant effects
and covariates with time-varying effects on 5-year DOS are
shown. Age at diagnosis demonstrated a time-constant effect,
with 5-year DOS being a quadratic function of age (supplemen-
tary Appendix S2, available at Annals of Oncology online).
Interestingly, high-risk nodal stage (N2/N3), compared with
N0, demonstrated a significant time-varying effect on 5-year
DOS with each successive tP, while nodal stage N1 did not
(Figure 3A). To illustrate, the HR of a patient with nodal stage
N2/N3 immediately after primary treatment compared with a
patient with nodal stage N0 (reference) is 3.621, calculated by
the following formula (Table 2):
HR ¼ ½constant  ðtime-varying effectÞtP  ¼ 3:621 0:8160;
but decreases to 2.401 (HR = 3.621 × 0.8162) at 2 years after the
start of ET. HER2-positive status also demonstrated a significant
time-varying effect on 5-year DOS (Table 2, Figure 3B).
Table 1. Baseline characteristics of patients included in the cohort
(N = 2602)
Characteristic n (%)
Age at diagnosis (years) (mean, standard deviation) 64.8 (9.19)
Tumor stage
T1 (<2 cm) 1135 (44%)
T2 (2–<5 cm) 1276 (49%)
T3/T4 (≥5 cm) 191 (7%)
Nodal stage
N0 821 (32%)
N1 1344 (52%)
N2/N3 437 (17%)
Histological grade (BR)
BR I 382 (15%)
BR II 1202 (46%)
BR III 1018 (39%)
Estrogen receptor status
Negative 57 (2%)
Positive 2545 (98%)
Progesterone receptor status
Negative 579 (22%)
Positive 2023 (78%)
HER2 status
Negative 1898 (73%)
Positive 257 (10%)
Missing 447 (17%)
Most extensive surgery
Mastectomy 1422 (55%)
Breast-conserving surgery 1180 (45%)
Radiotherapy
Yes 1718 (66%)
No 884 (34%)
Chemotherapy
Yes 843 (32%)
No 1759 (68%)
BR, Bloom and Richardson.
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Next, covariates whose status have the potential to change
over time (i.e. treatment compliance status and disease recur-
rence) were investigated for their influence on 5-year mortality
risk. Patients who went off-treatment during the FU period had
a higher residual mortality risk compared with patients who
remained compliant, although this was not statistically signifi-
cant. The effect of treatment discontinuation was constant over
time (Table 2). Simultaneously, LRR had a time-varying influ-
ence on 5-year DOS, revealing a subsiding mortality risk with
each successive tLM (Figure 3C). Compared with no LRR, having
a LRR at 1, 2, and 3 years after the start of ET increased 5-year
mortality risk with HR = 4.913 (2.444–9.877), HR = 2.864
(1.851–4.431), and HR = 1.670 (1.005–2.773), respectively
(Table 2). In contrast, developing distant metastases (versus no
distant metastases) was associated with an increased 5-year
mortality risk, with a constant effect over time [HR = 15.018
(9.934–22.705)].
Figure 4 illustrates differences in the 5-year DOS in the event
of a LRR in a patient who presents with the most commonly
occurring baseline characteristics (average patient) found in this
cohort, as well as in a high-risk patient. In the absence of a LRR,
5-year mortality probabilities are ∼3% and 10%, respectively, at
all tPs. However, in case of a LRR, 5-year mortality probabilities
in both the average patient and the high-risk patient are initially
high, and decrease with time.
internal model validation
The heuristic shrinkage factor was 0.995, indicating good cali-
bration of the model. Furthermore, the model’s discriminatory
accuracy had a dynamic cross-validated c-index of 0.70, 0.72,
0.76, and 0.79 at 0, 1, 2, and 3 years respectively.
using the nomogram
The nomogram (Figure 5) provides estimates for 5-year DOS
probabilities at different tPs from the start of ET and onwards,
provided that adequate surgery has been carried out. The prob-
abilities can be calculated by adding the risk points for each
covariate corresponding to the patient’s individual characteris-
tics. For each characteristic, the number of associated risk
points can be determined by drawing a vertical line straight up
from the covariate’s corresponding value to the axis with risk
points (0–80). While the majority of covariates are considered
‘static’ and defined at the start of ET, some covariates are
‘dynamic’, and can alter during the course of FU, such as treat-
ment compliance status and the occurrence of LRR or distant
metastases during FU. The covariates marked with ‘(tP)’ (pre-
diction timepoint) include nodal stage (N2/3), HER2 status
(positive), and LRR (yes), and have time-varying effects on 5-
year DOS. This means that the effect of having characteristics
that pertain to one these specific covariates varies as the time
2000
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Figure 2. Number of patients at risk in relation to follow-up time since the start of endocrine treatment. Number of patients in the landmark datasets
(i.e. at risk) over time (tLM) since the start of adjuvant endocrine treatment in relation to (A) treatment compliance status (on-treatment/off-treatment)
(B) distant recurrence status (yes, no) and (C) locoregional recurrence status (yes, no).
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since starting treatment progresses and that the time since the
start of ET needs to be taken into account when making a
5-year DOS prediction.
The sum of the risk points is equal to the total risk point
score, which is depicted on the axis of the nomogram entitled
‘Total Points’. From here, a vertical line can be drawn toward
the axis labeled ‘5-year survival probability’, which is the corre-
sponding 5-year DOS at that specific tP.
To illustrate, we consider a 69-year-old postmenopausal woman
(14 points) who has been using ET for two years (tP = 2; 191
Table 2. The dynamic prediction model with time-constant and time-varying covariates
Regression coefficient Hazard ratio (95% CI) P value
Covariates with time-constant effects
Age at diagnosis (ref: 65 years, per 10 years) <0.001
Age 0.365 1.440 (1.254–1.653)
Age2 0.154 1.166 (1.067–1.275)
Tumor size [ref: T1 (<2 cm)] <0.001
T2 (2–<5 cm) 0.256 1.291 (1.052–1.585)
T3/T4 (≥5 cm) 0.306 1.357 (0.956–1.928)
Histological grade (BR) (ref: BR I) 0.001
BR II −0.018 0.982 (0.729–1.323)
BR III 0.346 1.413 (1.038–1.923)
Estrogen receptor status (ref: positive) 0.073
Negative 0.566 1.761 (0.948–3.271)
Progesterone receptor status (ref: positive) <0.001
Negative 0.456 1.557 (1.301–1.913)
Most extensive surgery (ref: mastectomy) 0.683
Breast-conserving surgery 0.055 1.057 (0.811–1.377)
Radiotherapy (ref: yes) 0.157
No 0.195 1.216 (0.928–1.592)
Chemotherapy (ref: yes) 0.384
No 0.127 1.136 (0.853–1.512)
Treatment status (ref: on-treatment) 0.224
Off-treatment 0.234 1.263 (0.867–1.841)
Distant recurrence (ref: no) <0.001
Yes 2.709 15.018 (9.934–22.705)
Covariates with time-varying effectsa
Prediction time (ref: years since start of treatmentb) 0.057
tP 0.017 1.017 (0.920–1.125)
tP
2 −0.034 0.967 (0.945–0.989)
Nodal stage (ref: N0) <0.001
Constant
N1 0.303 1.354 (1.021–1.795)
N2/N3 1.287 3.621 (2.596–5.052)
Time-varying effect 0.026
N1 (tP) −0.047 0.954 (0.869–1.048)
N2/N3 (tP) −0.204 0.816 (0.722–0.922)
HER2 status (ref: HER2 negative) 0.214
Constant
Positive 0.211 1.235 (0.885–1.724)
Time-varying effect 0.015
Positive (tP) −0.162 0.851 (0.747–0.969)
Locoregional recurrence (ref: no LRR) <0.001
Constant
LRR 2.131 8.427 (2.885–24.617)
Time-varying effect 0.013
LRR (tP) −0.540 0.583 (0.380–0.893)
Age2 refers to the quadratic effect of age at diagnosis on 5-year dynamic overall survival (DOS); tP
2 refers to the quadratic effect of prediction time (tP)
on 5-year DOS.
aSpecific hazard ratios (HR) for time-varying covariates are calculated by the following formula: HR ¼ ½constant ðtime-varying effectÞtP .
bTime elapsed (years) since the start of adjuvant endocrine treatment.
CI, confidence interval; tP, prediction timepoint; BR, Bloom and Richardson; LRR, locoregional recurrence.
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points). She had a grade III tumor (13 points) with a diameter of
1.5 cm (0 points), ER-positive (0 points), PR-positive (0 points)
and HER2-negative (10 points), and 5 tumor-positive lymph
nodes (at tP = 2; 32 points). The patient has undergone breast-con-
serving surgery (2 points) with adjuvant radiotherapy (0 points)
and adjuvant chemotherapy (0 points). She is still on-treatment
(0 points) and disease-free (0 points) (no locoregional or DR). To
calculate her 5-year DOS probability, we take her total risk point
score (90 points) and draw a vertical line down to the ‘5-year sur-
vival probability’ axis. For this patient, the 5-year DOS is 75%. If
our patient had developed a LRR in the 2-year period since ET,
one must add an additional 38 points (total = 128 points) to her
total risk prediction score, resulting in a 5-year DOS of 42%.
discussion
To our knowledge, this is the first dynamic prediction model in
clinical oncology, designed to optimize the prediction of the
5-year DOS at specific timepoints after the start of adjuvant ET
in postmenopausal, endocrine-sensitive early BC patients. The
key advantage of this model is that it takes into account dynamic
factors that can influence a patient’s prognosis after some time
has passed since starting ET, including treatment compliance and
the occurrence of LRR or distant metastases. Moreover, covariates
with time-varying effects are also accounted for in the model, in-
cluding high-risk nodal stage (N2/3) and HER2-positive status.
Current nomograms are suboptimal for cancer patients,
because their reference point is commonly the time of diagnosis
or the start of adjuvant ET. Aiming at further personalized BC
treatment, continuous re-evaluation of the residual risk of BC
recurrence and mortality during FU is crucial. Patients may
develop disease recurrences or discontinue ET before the prede-
signated end-date, which may alter a patient’s prognosis from
that timepoint onward. Additionally, the effect of a covariate on
5-year survival probabilities may not be constant over time.
These changes are more prominent than current statistical
models account for, which could lead to the risk of developing
less effective treatment guidelines. Therefore, survival prediction
models need to be adapted for long-term outcome prediction in
individual patients. Specifically, dynamic prediction models can
be used to determine whether a patient will benefit from further
adjuvant systemic therapy or, conversely, whether ET can be
discontinued at a certain timepoint during FU.
The current nomogram can be applied to postmenopausal,
HR+ BC patients undergoing adjuvant ET and have had an axil-
lary lymph node dissection in case of macrometastases. For
patients who have had breast-conserving surgery, the model
assumes that the breast was irradiated. The current nomogram
also assumes that disease relapse implies discontinuation of ET
from that moment onward. In case of disease recurrence, data
on subsequent treatment were not available for all patients;
hence, our ability to draw conclusions for this subgroup is
limited.
LRR is considered a ‘dynamic’ covariate, as patients can
develop a LRR at any moment during FU. LRR also had ‘time-
varying’ properties, as the event of a LRR revealed a changing
impact on 5-year DOS at different timepoints after starting ET.
Our findings parallel those of several other studies, which have
shown that early LRRs are predictive of a worse prognosis than
late LRRs [12–16]. It can therefore be of major clinical import-
ance to include this factor in dynamic survival prediction.
Moreover, this model could potentially help evaluate the need
for additional adjuvant chemotherapy in case of LRR. Data
on the benefit of additional chemotherapy are still relatively
lacking, although the nomogram could be useful in this setting.
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Figure 3. Time-varying hazard ratios for nodal stage, HER2 status, and
locoregional recurrence status. tP, prediction timepoint; LRR, locoregional
recurrence. Hazard ratios for nodal stage, HER2 status, and locoregional re-
currence status as time since the start of endocrine treatment (tP) increases
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The current model also revealed a time-varying relationship
between high nodal stage (N2/3) and 5-year DOS probability.
A similar time-varying effect was shown with regard to 5-year
DOS in HER2-positive patients, although no patients received
anti-HER2 treatment. To our knowledge, no prior reports have
investigated the time-varying effects of these two prognostic
factors, hence warranting further investigation.
Our dynamic prediction model also accounts for the effect of
early treatment discontinuation for reasons other than BC
relapse. Although the effect of treatment discontinuation did
not reach statistical significance, possibly due to the low number
of patients who discontinued treatment within three years
(Figure 2, left panel), we retained this data in our model, as an
earlier review revealed the importance of treatment compliance
on survival outcomes [17].
The number and site(s) of DR are known to be prognostic
for subsequent survival [18–20]. The dynamic prediction
model incorporates the occurrence of distant metastases, but
does not include this in the nomogram due to insufficient data
concerning first site of DR and subsequent treatment. For this
reason, it is not advised to use the dynamic prediction
model for patients with distant metastases as first site of
disease recurrence.
Internal validation demonstrated that the model had a good
ability to discriminate between patients. To elucidate, internal
validation of Adjuvant! showed a c-index of 0.71 for discrimin-
atory accuracy (the ability for the model to distinguish patients
who will versus those who will not die of BC) and a predictive
accuracy of 0.73 at diagnosis, which is similar to that of our pre-
diction model [21]. The predictive accuracy of Adjuvant! ‘after
diagnosis’ has not been studied; in contrast, our dynamic
prediction model showed a cross-validated c-index that
improved from 0.70 to 0.79 3 years after the start of
adjuvant ET.
Due to the unavailability of regular FU data for the entire
TEAM trial population, our dynamic prediction model includes
Dutch and Belgian TEAM trial patients only. As shown in sup-
plementary Table S1, available at Annals of Oncology online,
characteristics of the Dutch trial population differed slightly in
comparison to the rest of the TEAM trial population. These dif-
ferences depict that patients in current cohort have a slightly
higher disease stage and subsequent variations in treatment.
The dynamic prediction model is a multivariate model that cor-
rects for each of these variables. Therefore, inclusion of the
entire TEAM trial population in the model could alter individ-
ual predictions. Importantly, however, this is not expected to
affect the ‘correctness’ of the model, which would only be
affected in case of lack of model fit. Of note, one must also con-
sider that any trial population is not representative of the
general BC population as a whole. For this reason, further exter-
nal validation of the prediction model is required in greater
(non-trial) cohorts to allow for full applicability in the clinical
setting. An independent population with adequate FU data for
performing an external validation of the dynamic prediction
model was not available at the time of conducting this study.
In summary, the importance of using dynamic prediction
models for clinical guidance, not only at the start of treatment,
but also during FU, permits continuous revision of a patient’s re-
sidual mortality risk and can help motivate a patient to continue
treatment, improve compliance, and ultimately improve survival.
This proof-of-principle study demonstrates a novel technique for
performing dynamic prediction of BC survival probabilities over
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Figure 4. Change in 5-year dynamic probabilities of death based on the occurrence of a locoregional recurrence in two example patients. tP, prediction time-
point; LRR, locoregional recurrence; ER, estrogen receptor; PR, progesterone receptor. This figure illustrates how 5-year dynamic probabilities of death changes
if a patient who is on-treatment throughout the entire follow-up period develops a LRR during follow-up. Two example patients are depicted in (A) and (B).
(A) Average patient with the following characteristics: age at diagnosis = 65 years, tumor stage T2, nodal stage N1, histological grade II (Bloom and
Richardson), HER2 negative, ER and PR positive, treated with breast-conserving surgery, adjuvant radiotherapy and adjuvant chemotherapy. (B) High-risk
patient with the following characteristics: age at diagnosis = 65 years, tumor stage T3, nodal stage N2, histological grade III (Bloom and Richardson), HER2
negative, ER and PR positive, treated with mastectomy, adjuvant radiotherapy and adjuvant chemotherapy.
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Figure 5. Nomogram for dynamic prediction of the 5-year survival probability. BR, Bloom and Richardson; BCS, breast-conserving surgery; tP, prediction timepoint. The 5-year dynamic overall survival (DOS)
probability is calculated by taking the sum of the risk points, according to patient-, tumor-, and treatment-specific characteristics. For each covariate, the number of associated risk points can be determined by
drawing a vertical line straight up from the covariate’s corresponding value (as determined by the individual patient’s characteristics) to the axis with risk points (0–80). All covariates marked with ‘(tP)’ have time-
varying effects and require that the time since the start of endocrine treatment are taken into account. For each covariate with a time-changing effect (nodal status, HER2 status, LRR, and prediction timepoint (tP),
the values on the line represent the timepoint after the start of endocrine treatment at which the prediction is being made (0–3 years after the start of endocrine treatment).
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time, enabling a more individualized prediction of the 5-year
DOS in individual patients at various timepoints during adjuvant
ET. The most important advantage of this model is that it takes
into account factors that can influence an individual patient’s
prognosis after some time has passed since starting adjuvant ET.
Notwithstanding the feasibility of our dynamic prediction model,
further external validation with longer FU is necessary to enable
implementation in clinical practice.
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